

## Peter Mac publications 2022

### January

1. Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliogy M, Lin X, Czibere A, Fizazi K. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. *Future Oncol* 2022;18:425-36.
2. Aide N, Iravani A, Prigent K, Kottler D, Alipour R, Hicks RJ. PET/CT variants and pitfalls in malignant melanoma. *Cancer Imaging* 2022;22:3.
3. Anton A, Tran B. Global Disparity in Access to Novel Therapeutics for Metastatic Prostate Cancer. *JCO Oncol Pract* 2022;18:57-9.
4. Archer C, Veall J, Duggan LV, Downey A, Rose P. A comparison of patient and provider perceptions of awake tracheal intubations. *Can J Anaesth* 2022;69:179-81.
5. Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M, Benitez J, Berthet P, Boonen SE, Borg Å, Bozsik A, Brady AF, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Caldés T, Caligo MA, Campbell I, Cassingham H, Christensen LL, Cini G, Claes KBM, Cook J, Coppa A, Cortesi L, Damante G, Darder E, Davidson R, de la Hoya M, De Leeneer K, de Putter R, Del Valle J, Diez O, Ding YC, Domchek SM, Donaldson A, Eason J, Eeles R, Engel C, Evans DG, Feliubadaló L, Fostira F, Frone M, Frost D, Gallagher D, Gehrig A, Giraud S, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gregory H, Gross E, Hahnen E, Hamann U, Hansen TVO, Hanson H, Hentschel J, Horvath J, Izatt L, Izquierdo A, James PA, Janavicius R, Jensen UB, Johannsson OT, John EM, Kramer G, Kroeldrup L, Kruse TA, Lautrup C, Lazaro C, Lesueur F, Lopez-Fernández A, Mai PL, Manoukian S, Matrai Z, Matricardi L, Maxwell KN, Mebirouk N, Meindl A, Montagna M, Monteiro AN, Morrison PJ, Muranen TA, Murray A, Nathanson KL, Neuhausen SL, Nevanlinna H, Nguyen-Dumont T, Niederacher D, Olah E, Olopade OI, Palli D, Parsons MT, Pedersen IS, Peissel B, Perez-Segura P, Peterlongo P, Petersen AH, Pinto P, Porteous ME, Pottinger C, Pujana MA, Radice P, Ramser J, Rantala J, Robson M, Rogers MT, Rønlund K, Rump A, Sánchez de Abajo AM, Shah PD, Sharif S, Side LE, Singer CF, Stadler Z, Steele L, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teulé A, Thull DL, Tischkowitz M, Toland AE, Tommasi S, Toss A, Trainer AH, Tripathi V, Valentini V, van Asperen CJ, Venturelli M, Viel A, Vijai J, Walker L, Wang-Gohrke S, Wappenschmidt B, Whaite A, Zanna I, Offit K, Thomassen M, Couch FJ, Schmutzler RK, Simard J, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *J Natl Cancer Inst* 2022;114:109-22.
6. Body A, Wong R, Shapiro J, Jalali A, McLachlan SA, Ananda S, Lipton L, Cooray P, Gibbs P, Lee B, Lee M. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia. *Intern Med J* 2022;52:49-56.
7. Bournazos AM, Riley LG, Bommireddipalli S, Ades L, Akesson LS, Al-Shinnag M, Alexander SI, Archibald AD, Balasubramaniam S, Berman Y, Beshay V, Boggs K, Bojadzieva J, Brown NJ, Bryen SJ, Buckley MF, Chong B, Davis MR, Dawes R, Delatycki M, Donaldson L, Downie L, Edwards C, Edwards M, Engel A, Evans LJ, Faiz F, Fennell A, Field M, Freckmann ML, Gallacher L, Gear R, Goel H, Goh S, Goodwin L, Hanna B, Harraway J, Higgins M, Ho G, Hopper BK, Horton AE, Hunter MF, Huq AJ, Josephi-Taylor S, Joshi H, Kirk E, Krzesinski E, Kumar KR, Lemckert F, Leventer RJ, Lindsey-Temple SE, Lunke S, Ma A, Macaskill S, Mallawaarachchi A, Marty M, Marum JE, McCarthy HJ, Menezes MP, McLean A, Milnes D, Mohammad S, Mowat D, Niaz A, Palmer EE, Patel C, Patel SG, Phelan D, Pinner JR, Rajagopalan S, Regan M, Rodgers J, Rodrigues M, Roxburgh RH, Sachdev R, Roscioli T, Samarasekera R, Sandaradura SA, Savva E, Schindler T, Shah M, Sinnerbrink IB, Smith JM, Smith RJ, Springer A, Stark Z, Strom SP, Sue CM, Tan K, Tan TY, Tantsis E, Tchan MC, Thompson BA, Trainer AH, van Spaendonck-Zwarts K, Walsh R, Warwick L, White S, White SM, Williams MG, Wilson MJ, Wong WK, Wright DC, Yap P, Yeung A, Young H, Jones KJ, Bennetts B, Cooper ST. Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants. *Genet Med* 2022;24:130-45.

8. Brodsky RA, Lee JW, Nishimura JI, Szer J. Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria? *Br J Haematol* 2022;196:264-5.
9. Brown L, Loveday B. Acute pancreatitis in Australian adults: can administrative data help with healthcare planning? *ANZ J Surg* 2022;92:8-9.
10. Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. Ibrutinib plus Rituximab Versus Placebo plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis from the Randomized Phase III iNOVATE Study. *J Clin Oncol* 2022;40:52-62.
11. Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. *Cochrane Database Syst Rev* 2022;1:CD013453.
12. Carmichael L, Rocca R, Laing E, Ashford P, Collins J, Jackson L, McPherson L, Pendergast B, Kiss N. Early postoperative feeding following surgery for upper gastrointestinal cancer: A systematic review. *J Hum Nutr Diet* 2022;35:33-48.
13. Chau TCY, Baek S, Coxam B, Skoczylas R, Rondon-Galeano M, Bower NI, Wainwright EN, Stacker SA, Cooper HM, Koopman PA, Lagendijk AK, Harvey NL, François M, Hogan BM. Pkd1 and Wnt5a genetically interact to control lymphatic vascular morphogenesis in mice. *Dev Dyn* 2022;251:336-49.
14. Chen K, Murphy D, Lawrentschuk N. Active Surveillance for Low-Risk Prostate Cancer: The Uphill Battles and the Unnecessary Ones. *J Urol* 2022;207:265-7.
15. Chi LH, Burrows AD, Anderson RL. Can preclinical drug development help to predict adverse events in clinical trials? *Drug Discov Today* 2022;27:257-268.
16. Choi PY, Merriman E, Bennett A, Enjeti AK, Tan CW, Goncalves I, Hsu D, Bird R. Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. *Med J Aust* 2022;216:43-52.
17. Chong E, Ratnayake B, Dasari BVM, Loveday BPT, Siriwardena AK, Pandanaboyana S. Adjuvant Chemotherapy in the Treatment of Intraductal Papillary Mucinous Neoplasms of the Pancreas: Systematic Review and Meta-Analysis. *World J Surg* 2022;46:223-34.
18. Cousin S, Blay JY, Garcia IB, de Bono JS, Le Tourneau C, Moreno V, Trigo J, Hann CL, Azad AA, Im SA, Cassier PA, French CA, Italiano A, Keedy VL, Plummer R, Sablin MP, Hemming ML, Ferron-Brady G, Wyce A, Khaled A, Datta A, Foley SW, McCabe MT, Wu Y, Horner T, Kremer BE, Dhar A, O'Dwyer PJ, Shapiro GI, Piha-Paul SA. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. *Int J Cancer* 2022;150:993-1006.
19. Crowe J, Francis JJ, Edbrooke L, Loeliger J, Joyce T, Prickett C, Martin A, Khot A, Denehy L. Impact of an allied health prehabilitation service for haematologic patients receiving high-dose chemotherapy in a large cancer centre. *Support Care Cancer* 2022;30:1841-52.
20. Davidson NM, Chen Y, Sadras T, Ryland GL, Blombery P, Ekert PG, Göke J, Oshlack A. JAFFAL: detecting fusion genes with long-read transcriptome sequencing. *Genome Biol* 2022;23:10.
21. Deftereos I, Yeung JM, Arslan J, Carter VM, Isenring E, Kiss N. Adherence to ESPEN guidelines and associations with postoperative outcomes in upper gastrointestinal cancer resection: results from the multi-centre NOURISH point prevalence study. *Clin Nutr ESPEN* 2022;47:391-8.
22. Degeling K, IJzerman MJ, Groothuis-Oudshoorn CGM, Franken MD, Koopman M, Clements MS, Koffijberg H. Comparing Modeling Approaches for Discrete Event Simulations with Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer. *Value Health* 2022;25:104-15.

23. Delahunt B, Steigler A, Atkinson C, Christie D, Duchesne G, Egevad L, Joseph D, Kenwright DN, Matthews J, Murray JD, Oldmeadow C, Samaratunga H, Spry NA, Thunders MC, Hondermarck H, Denham JW. Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial. *Pathology* 2022;54:49-54.
24. Delany C, Milch V, Keefe D, Wong ZW. COVID-19 recovery: implications for cancer care clinicians. *Support Care Cancer* 2022;30:1003-6.
25. Dervisevic E, Voelcker NH, Risbridger G, Tuck KL, Cadarso VJ. Colorimetric Detection of Extracellular Hydrogen Peroxide Using an Integrated Microfluidic Device. *Anal Chem* 2022;94:1726-32.
26. Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. *Nat Rev Cancer* 2022;22:45-64.
27. Edbrooke L, Khaw P, Freimund A, Carpenter D, McNally O, Joubert L, Loeliger J, Traill A, Gough K, Mileskin L, Denehy L. ENhancing Lifestyle Behaviors in Endometrial CancEr (ENABLE): A Pilot Randomized Controlled Trial. *Integr Cancer Ther* 2022;21:15347354211069885.
28. Ewe KYH, Blyth CC, McLeod C, Borland ML, Bowen AC, Yeoh DK, Campbell AJ. Re-examining Hepatitis B Postexposure Prophylaxis Following Pediatric Community-acquired Needle-stick Injury in an Era of a National Immunization Registry. *Pediatr Infect Dis J* 2022;41:80-84.
29. Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P, Nye M. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply. *Lancet Oncol* 2022;23:e14-e15.
30. Fennell KA, Vassiliadis D, Lam EYN, Martelotto LG, Balic JJ, Hollizeck S, Weber TS, Semple T, Wang Q, Miles DC, MacPherson L, Chan YC, Guirguis AA, Kats LM, Wong ES, Dawson SJ, Naik SH, Dawson MA. Non-genetic determinants of malignant clonal fitness at single-cell resolution. *Nature* 2022;601:125-31.
31. Ferguson MT, Kusre S, Myles PS. Minimal clinically important difference in days at home up to 30 days after surgery. *Anaesthesia* 2022;77:196-200.
32. Fidelito G, Watt MJ, Taylor RA. Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? *Front Oncol* 2022;11:778761.
33. Flood M, Narasimhan V, Wilson K, Lim WM, Ramsay R, Michael M, Heriot A. ASO Visual Abstract: Organoids as a Robust Preclinical Model for Precision Medicine in Colorectal Cancer-A Systematic Review. *Ann Surg Oncol* 2022;29:62-3.
34. Flood M, Narasimhan V, Wilson K, Lim WM, Ramsay R, Michael M, Heriot A. Organoids as a Robust Preclinical Model for Precision Medicine in Colorectal Cancer: A Systematic Review. *Ann Surg Oncol* 2022;29:47-59.
35. Flood M, Ramsay R, Heriot A. ASO Author Reflections: Organoid-Based Precision Medicine in Colorectal Cancer-Are We There Yet? *Ann Surg Oncol* 2022;29:60-1.
36. Forbes Shepherd R, Werner-Lin A, Keogh LA, Delatycki MB, Forrest LE. Reproduction and Genetic Responsibility: An Interpretive Description of Reproductive Decision-Making for Young People With Li-Fraumeni Syndrome. *Qual Health Res* 2022;32:168-181.
37. Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, Yagubbayli F, Kratochwil C, Grogan TR, Nguyen K, Navarro F, Esfandiari R, Rauscher I, Menze B, Elashoff D, Delpassand ES, Herrmann K, Czernin J, Hofman MS, Calais J, Fendler WP, Eiber M. Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality? *J Nucl Med* 2022;63:226-32.
38. Gates P, Dhillon H, Gough K, Wilson C, Hawkes E, Scudder L, Cushion T, Krishnasamy M. Exploration of motivation to participate in a study of cancer-related cognitive impairment among patients with newly diagnosed aggressive lymphoma: a qualitative sub-study. *Support Care Cancer* 2022;30:1331-9.

39. Granger CL, Edbrooke L, Antippa P, Wright G, McDonald CF, Lamb KE, Irving L, Krishnasamy M, Abo S, Whish-Wilson GA, Truong D, Denehy L, Parry SM. Effect of a postoperative home-based exercise and self-management programme on physical function in people with lung cancer (CAPACITY): protocol for a randomised controlled trial. *BMJ Open Respir Res* 2022;9:e001189.
40. Guccione L, Gough K, Drosdowsky A, Price T, Pavlakis N, Wyld D, Ransom D, Michael M, Schofield P. The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning neuroendocrine tumours (NETs) at early diagnosis. *Patient Educ Couns* 2022;105:212-20.
41. Hagberg CA, Nates JL, Riedel B, Gottumukkala VNR, Buggy D (Eds). *Perioperative Care of the Cancer Patient*. Elsevier, Cambridge, MA, USA, 2022.
42. Harvey M, Chislett B, Perera M, Lawrentschuk N, Bolton D, Jack G. Critical shortage in BCG immunotherapy: How did we get here and where will it take us? *Urol Oncol* 2022;40:1-3.
43. Hicks R, Czernin J, Herrmann K. Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann. *J Nucl Med* 2022;63:1-4.
44. Howard-Jones AR, Bowen AC, Danchin M, Koirala A, Sharma K, Yeoh DK, Burgner DP, Crawford NW, Goeman E, Gray PE, Hsu P, Kuek S, McMullan BJ, Tosif S, Wurzel D, Britton PN. COVID-19 in children: I. Epidemiology, prevention and indirect impacts. *J Paediatr Child Health* 2022 Jan;58:39-45.
45. Howard-Jones AR, Burgner DP, Crawford NW, Goeman E, Gray PE, Hsu P, Kuek S, McMullan BJ, Tosif S, Wurzel D, Bowen AC, Danchin M, Koirala A, Sharma K, Yeoh DK, Britton PN. COVID-19 in children. II: Pathogenesis, disease spectrum and management. *J Paediatr Child Health* 2022;58:46-53.
46. Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. *J Nucl Med* 2022;63:59-68.
47. John T, Taylor A, Wang H, Eichinger C, Freeman C, Ahn MJ. Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes. *Cancer Epidemiol* 2022;76:102080.
48. Kok PS, Lee K, Lord S, John T, Marschner I, Wu YL, Mok TSK, Lee CK. Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. *Lung Cancer* 2022;163:14-8.
49. Kusnadi EP, Timpone C, Topisirovic I, Larsson O, Furic L. Regulation of gene expression via translational buffering. *Biochim Biophys Acta Mol Cell Res* 2022;1869:119140.
50. Li H, Engel C, de la Hoya M, Peterlongo P, Yannoukakos D, Livraghi L, Radice P, Thomassen M, Hansen TVO, Gerdes AM, Nielsen HR, Caputo SM, Zambelli A, Borg A, Solano A, Thomas A, Parsons MT, Antoniou AC, Leslie G, Yang X, Chenevix-Trench G, Caldes T, Kwong A, Pedersen IS, Laurrup CK, John EM, Terry MB, Hopper JL, Southey MC, Andrulis IL, Tischkowitz M, Janavicius R, Boonen SE, Kroeldrup L, Varesco L, Hamann U, Vega A, Palmero EI, Garber J, Montagna M, Van Asperen CJ, Foretova L, Greene MH, Selkirk T, Moller P, Toland AE, Domchek SM, James PA, Thorne H, Eccles DM, Nielsen SM, Manoukian S, Pasini B, Caligo MA, Lazaro C, Kirk J, Wappenschmidt B, Spurdle AB, Couch FJ, Schmutzler R, Goldgar DE. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. *Genet Med* 2022;24:119-29.
51. Lim BWX, Li N, Rowley SM, Thompson ER, McInerney S, Zethoven M, Scott RJ, Devereux L, Sloan EK, James PA, Campbell IG. Integration of tumour sequencing and case-control data to assess pathogenicity of RAD51C missense variants in familial breast cancer. *NPJ Breast Cancer* 2022;8:10.
52. Lin T, Pham J, Paul E, Conron M, Wright G, Ball D, Mitchell P, Atkin N, Brand M, Zalcborg J, Stirling RG. Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study. *Lung Cancer* 2022;163:69-76.

53. Lippey J, Keogh L, Campbell I, Mann GB, Forrest L. Development and pilot testing of an online decision aid for women considering risk-stratified breast screening. *J Community Genet* 2022;13:137-41.
54. Liu Z, Martin JH, Liauw W, McLachlan SA, Link E, Matera A, Thompson M, Jefford M, Hicks RJ, Cullinane C, Hatzimihalis A, Campbell I, Crowley S, Beale PJ, Karapetis CS, Price T, Burge ME, Michael M. Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites. *Eur J Clin Pharmacol* 2022;78:53-64.
55. Livingston PM, Russell L, Orellana L, Winter N, Jefford M, Girgis A, Austin D, O E, Mihalopoulos C, Ugalde A, Chambers R, Phipps-Nelson J, Herath D, Botti M, Rasmussen B, Whitfield K, Ftanou M, Smith AB, Pilatti K, Sara S, Wootten A, Gillan K, Singh M, Campbell D, Pillay B, White V. Efficacy and cost-effectiveness of an online mindfulness program (MindOnline) to reduce fear of recurrence among people with cancer: study protocol for a randomised controlled trial. *BMJ Open* 2022;12:e057212.
56. Lloyd P, Hong A, Furrer MA, Lee EWY, Dev HS, Coret MH, Adshead JM, Baldwin P, Knight R, Shamash J, Alifrangis C, Stoneham S, Mazhar D, Wong H, Warren A, Tran B, Lawrentschuk N, Neal DE, Thomas BC. A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. *World J Urol* 2022;40:119-126.
57. Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, Roblin E, Michiels S. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. *NPJ Breast Cancer* 2022;8:3.
58. Lucas CG, Gupta R, Wu J, Shah K, Ravindranathan A, Barreto J, Gener M, Ginn KF, Prall OWJ, Xu H, Kee D, Ko HS, Yaqoob N, Zia N, Florez A, Cha S, Perry A, Clarke JL, Chang SM, Berger MS, Solomon DA. EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. *Acta Neuropathol* 2022;143:109-13.
59. Masle-Farquhar E, Peters TJ, Miosge LA, Parish IA, Weigel C, Oakes CC, Reed JH, Goodnow CC. Uncontrolled CD21<sup>low</sup> age-associated and B1 B cell accumulation caused by failure of an EGR2/3 tolerance checkpoint. *Cell Rep* 2022;38:110259.
60. Mato AR, Sharman JP, Biondo JML, Wu M, Mun Y, Kim SY, Humphrey K, Boyer M, Zhu Q, Seymour JF. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study. *Haematologica* 2022;107:134-142.
61. McDowell L, Magarey M, Rischin D. Transoral surgery and deintensified adjuvant therapy: another step in determining its role in the management of human papillomavirus oropharyngeal cancer. *J Clin Oncol* 2022;40:114-117.
62. McLean LS, Lim AM, Webb A, Cavanagh K, Thai A, Magarey M, Fox C, Kleid S, Rischin D. Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma. *Front Oncol* 2022;11:796197.
63. Meiser B, Monnik M, Austin R, Nichols C, Cops E, Salmon L, Spurdle AB, Macrae F, Taylor N, Pachter N, James P, Kaur R. Stakeholder attitudes towards establishing a national genomics registry of inherited cancer predisposition: a qualitative study. *J Community Genet* 2022;13:59-73.
64. Mills G, Anderson MA, Tang C, Hamad N. The untold effect of the combined oral contraceptive pill on anticancer drugs. *Lancet Haematol* 2022;9:e10-e11.
65. Minson A, Hofman M, Dickinson M. A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse. *Leuk Lymphoma* 2022;63:1-4.
66. Muraro E, De Zorzi M, Miolo G, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Dolcetti R, Steffan A, De Re V. KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients with HER2-Positive Breast Cancer. *Front Immunol* 2022;12:791958.

67. Nguyen M, Segelov E, Goldstein D, Pavlakis N, Shapiro J, Price TJ, Nagrial A, Chantrill L, Leong T, Chen J, Burge M, Karapetis CS, Chau I, Lordick F, Renouf D, Tebbutt N, Roy AC. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. *Expert Rev Anticancer Ther* 2022;22:39-51.
68. Nguyen TK, Chin L, Sahgal A, Dagan R, Eppinga W, Guckenberger M, Kim JH, Lo SS, Redmond KJ, Siva S, Stish BJ, Chan R, Lawrence L, Lau A, Tseng CL. International Multi-institutional Patterns of Contouring Practice and Clinical Target Volume Recommendations for Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases. *Int J Radiat Oncol Biol Phys* 2022;112:351-60.
69. Perera MPJ, Thomas PB, Risbridger GP, Taylor R, Azad A, Hofman MS, Williams ED, Vela I. Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. *Cancers* 2022;14:503.
70. Piotin A, Godet J, Trubiano JA, Grandbastien M, Guénard-Bilbault L, de Blay F, Metz-Favre C. Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. *Ann Allergy Asthma Immunol* 2022;128:27-32.
71. Pitiyarachchi O, Phillips KA, Friedlander M. Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation. *Cancer Treat Res Commun* 2022;30:100504.
72. Qin VM, Haynes NM, D'Souza C, Neeson PJ, Zhu JJ. CAR-T plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors. *Front Immunol* 2022;12:813832.
73. Reifels L, Krishnamoorthy S, Kölves K, Francis J. Implementation Science in Suicide Prevention. *Crisis* 2022;43:1-7.
74. Rischin KJ, Mostaghim M, Rao A, Smith B, O'Brien TA, Trubiano JA, Frith K, McMullan B. ESCAPE-Allergy: Evaluating screening for children and adolescents with penicillin allergy. *J Paediatr Child Health* 2022;58:83-9.
75. Sammut SJ, Crispin-Ortuzar M, Chin SF, Provenzano E, Bardwell HA, Ma W, Cope W, Dariush A, Dawson SJ, Abraham JE, Dunn J, Hiller L, Thomas J, Cameron DA, Bartlett JMS, Hayward L, Pharoah PD, Markowitz F, Rueda OM, Earl HM, Caldas C. Multi-omic machine learning predictor of breast cancer therapy response. *Nature* 2022;601:623-9.
76. Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-Smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, McArthur GA, McLean CA, Menzies AM, Nieweg OE, O'Brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshildadze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AHR, Vilain RE, Wood BA, Long GV. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. *Pathology* 2022;54:6-19.
77. Seth N, Seth I, Bulloch G, Siu AHY, Guo A, Chatterjee R, MacManus M, Donnan L. <sup>18</sup>F-FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: A systematic review and meta-analysis. *Pediatr Blood Cancer* 2022;69:e29415.
78. Seymour JF. CLL12: a positive answer to a poorly phrased question. *Blood* 2022;139:151-2.
79. Shembrey C, Smith J, Grandin M, Williams N, Cho HJ, Mølck C, Behrenbruch C, Thomson BN, Heriot AG, Merino D, Hollande F. Longitudinal Monitoring of Intra-Tumoural Heterogeneity Using Optical Barcoding of Patient-Derived Colorectal Tumour Models. *Cancers* 2022;14:581.
80. Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. *Br J Haematol* 2022;196:488-506.
81. Szer J. The Journal in 2021. *Intern Med J* 2022;52:5-6.

82. Tammemägi MC, Ruparel M, Tremblay A, Myers R, Mayo J, Yee J, Atkar-Khattra S, Yuan R, Cressman S, English J, Bedard E, MacEachern P, Burrowes P, Quaife SL, Marshall H, Yang I, Bowman R, Passmore L, McWilliams A, Brims F, Lim KP, Mo L, Melsom S, Saffar B, Teh M, Sheehan R, Kuok Y, Manser R, Irving L, Steinfort D, McCusker M, Pascoe D, Fogarty P, Stone E, Lam DCL, Ng MY, Vardhanabhuti V, Berg CD, Hung RJ, Janes SM, Fong K, Lam S. USPSTF2013 versus PLOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. *Lancet Oncol* 2022;23:138-48.
83. Tan DS, Thomas M, Kim DW, Szpakowski S, Urban P, Mehra R, Chow LQM, Sharma S, Solomon BJ, Felip E, Camidge DR, Vansteenkiste J, Petruzzelli L, Pantano S, Shaw AT. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. *Lung Cancer* 2022;163:7-13.
84. Taylor EV, Lyford M, Parsons L, Holloway M, Gough K, Sabesan S, Thompson SC. Putting Policy into Practice: How Three Cancer Services Perform against Indigenous Health and Cancer Frameworks. *Int J Environ Res Public Health* 2022;19:633.
85. Tellambura M, Cumberbatch M, Goad J. A case of acute-colonic pseudo-obstruction (Ogilvie Syndrome) post robot-assisted radical prostatectomy. *Urol Case Rep* 2022;40:101878.
86. Thompson ER, Nguyen T, Kankanige Y, Markham JF, Anderson MA, Handunnetti SM, Thijssen R, Yeh PS, Tam CS, Seymour JF, Roberts AW, Westerman DA, Blombery P. Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors. *Blood Adv* 2022;6:503-8.
87. Tino RB, Yeo AU, Brandt M, Leary M, Kron T. A customizable anthropomorphic phantom for dosimetric verification of 3D-printed lung, tissue, and bone density materials. *Med Phys* 2022;49:52-69.
88. Toivanen R, Porter LH, Li Z, Clouston D, Risbridger GP, Taylor RA. Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification. *Cancer Lett* 2022;524:182-92.
89. Vasina EN, Greer P, Thwaites D, Kron T, Lehmann J. A system for real-time monitoring of breath-hold via assessment of internal anatomy in tangential breast radiotherapy. *J Appl Clin Med Phys* 2022;23:e13473.
90. Vervoort SJ, Devlin JR, Kwiatkowski N, Teng M, Gray NS, Johnstone RW. Targeting transcription cycles in cancer. *Nat Rev Cancer* 2022;22:5-24.
91. Visan KS, Lobb RJ, Wen SW, Bedo J, Lima LG, Krumeich S, Palma C, Ferguson K, Green B, Niland C, Cloonan N, Simpson PT, McCart Reed AE, Everitt SJ, MacManus MP, Hartel G, Salomon C, Lakhani SR, Fielding D, Möller A. Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients. *Cancers* 2022;14:257.
92. Wellinger LC, Hogg SJ, Newman DM, Friess T, Geiss D, Michie J, Ramsbottom KM, Bacac M, Fauti T, Marbach D, Jarassier L, Thienger P, Paehler A, Cluse LA, Kearney CJ, Vervoort SJ, Trapani JA, Oliaro J, Shortt J, Ruefli-Brasse A, Rohle D, Johnstone RW. BET Inhibition Enhances TNF-Mediated Antitumor Immunity. *Cancer Immunol Res* 2022;10:87-107.
93. Wheeler JCW, Keogh L, Sierra MA, Devereux L, Jones K, IJerman MJ, Trainer AH. Heterogeneity in how women value risk-stratified breast screening. *Genet Med* 2022;24:146-56.
94. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Long-Term Outcomes with Nivolumab plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients with Advanced Melanoma. *J Clin Oncol* 2022;40:127-37.
95. Wong AKY, Collins A, Ng A, Buizen L, Philip J, Le B. Evaluation of a Large Scale Advance Care Planning Co-Design Education Program for Chinese-Speaking People in Australia. *Am J Hosp Palliat Care* 2022;39:178-83.

96. Wortman BG, Post CCB, Powell ME, Khaw P, Fyles A, D'Amico R, Haie-Meder C, Jürgenliemk-Schulz IM, McCormack M, Do V, Katsaros D, Bessette P, Baron MH, Nout RA, Whitmarsh K, Mileskin L, Lutgens L, Kitchener HC, Brooks S, Nijman HW, Astreinidou E, Putter H, Creutzberg CL, de Boer SM. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2022;112:390-9.
97. Zidan L, Iravani A, Oleinikov K, Ben-Haim S, Gross DJ, Meirovitz A, Maimon O, Akhurst T, Michael M, Hicks RJ, Grozinsky-Glasberg S, Kong G. Efficacy and Safety of <sup>177</sup>Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicerter study. *J Nucl Med* 2022;63:218-25.
98. Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, de Oliveira JSR, Buccheri V, Perini GF, Dickinson M, McDonald A, Özcan M, Sekiguchi N, Zhu Y, Raut M, Saretsky TL, Nahar A, Kuruvilla J. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. *Blood Adv* 2022;6:590-9.

## February

1. Antill Y, Buchanan DD, Scott CL. Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer. *Cancer* 2022;128:1157-61.
2. Archer M, Dasari P, Walsh D, Britt KL, Evdokiou A, Ingman WV. Immune Regulation of Mammary Fibroblasts and the Impact of Mammographic Density. *J Clin Med* 2022;11:799.
3. Bartl AJ, Mahoney M, Hennon MW, Yendamuri S, Videtic GMM, Stephans KL, Siva S, Farrugia MK, Ma SJ, Singh AK. Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done. *Cancers* 2022;14:790.
4. Bishop MR, Dickinson M, Purtil D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Muller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jager U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. *N Engl J Med* 2022;386:629-39.
5. Blombery P, Lew TE, Dengler MA, Thompson ER, Lin VS, Chen X, Nguyen T, Panigrahi A, Handunnetti SM, Carney DA, Westerman DA, Tam CS, Adams JM, Wei AH, Huang DCS, Seymour JF, Roberts AW, Anderson MA. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. *Blood* 2022;139:1198-207.
6. Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, Bowtell DDL, Cramer DW, DeFazio A, Doherty JA, Fereday S, Fortner RT, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Matsuo K, Menon U, Modugno F, Moysich KB, Qin B, Ramus SJ, Risch HA, Rossing MA, Schildkraut JM, Trabert B, Vierkant RA, Winham SJ, Wentzensen N, Wu AH, Ziogas A, Khoja L, Cho KR, McLean K, Richardson J, Grout B, Chase A, Deurloo CM, Odunsi K, Nelson BH, Brenton JD, Terry KL, Pharoah PDP, Berchuck A, Hanley GE, Webb PM, Pike MC, Pearce CL, Ovarian Cancer Association Consortium. High prediagnosis inflammation-related risk score associated with decreased ovarian cancer survival. *Cancer Epidemiol Biomarkers Prev* 2022;31:443-452.
7. Bröske AE, Korfi K, Belousov A, Wilson S, Ooi CH, Bolen CR, Canamero M, Alcaide EG, James I, Piccione EC, Carlisle DJ, Dimier N, Umana P, Bacac M, Weisser M, Dickinson M. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. *Blood Adv* 2022;6:1025-37.



8. Bucknell NW, Gyorki DE, Bressel M, Estall V, Webb A, Henderson M, Chua MS, Rischin D, Tiong A. Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors. *Australas J Dermatol* 2022;63:43-52.
9. Chan S, Godsell J, Horton M, Farchione A, Howson LJ, Margetts M, Jin C, Chatelier J, Yong M, Sasadeusz J, Douglass JA, Slade CA, Bryant VL. Case Report: Cytomegalovirus Disease Is an Under-Recognized Contributor to Morbidity and Mortality in Common Variable Immunodeficiency. *Front Immunol* 2022;13:815193.
10. Cheung YT, Chan A, Charalambous A, Darling HS, Eng L, Grech L, van den Hurk CJG, Kirk D, Mitchell SA, Poprawski D, Rammant E, Ramsey I, Fitch MI, Chan RJ. The use of patient-reported outcomes in routine cancer care: preliminary insights from a multinational scoping survey of oncology practitioners. *Support Care Cancer* 2022;30:1427-1439.
11. Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Sail KR, Pesko J, Pai M, Komlosi V, Anderson MA. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. *Leuk Lymphoma* 2022;63:304-14.
12. Cribb BI, Kong J, McCormick J, Warriar SK, Heriot AG. Functional outcomes after lateral pelvic lymph node dissection for rectal cancer: a systematic review and meta-analysis. *Int J Colorectal Dis* 2022;37:583-95.
13. Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS. Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. *Br J Haematol* 2022;196:1209-18.
14. Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. *Ann Oncol* 2022;33:321-9.
15. Curtis AR, Livingstone KM, Daly RM, Marchese LE, Kiss N. Associations between Dietary Patterns and Malnutrition, Low Muscle Mass and Sarcopenia in Adults with Cancer: A Scoping Review. *Int J Environ Res Public Health* 2022;19:1769.
16. Deftereos I, Hitch D, Butzkueven S, Carter V, Fetterplace K, Fox K, Ottaway A, Pierce K, Steer B, Varghese J, Kiss N, Yeung JM. Implementing a standardised perioperative nutrition care pathway in upper gastrointestinal cancer surgery: a mixed-methods analysis of implementation using the Consolidated Framework for Implementation Research. *BMC Health Serv Res* 2022;22:256.
17. Dinh P, Graham JD, Elder EN, Kabir M, Doan TB, French J, Meybodi F, Hui R, Wilcken NR, Harnett PR, Hsu J, Stuart KE, Wang T, Ahern V, Brennan M, Fox SB, Dear RF, Lim E, White M, Mann GB, Pathmanathan N. Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing. *Breast Cancer Res Treat* 2022;191:501-511.
18. Feehan DD, Jamil K, Polyak MJ, Ogbomo H, Hasell M, Li SS, Xiang RF, Parkins M, Trapani JA, Harrison JJ, Mody CH. Natural killer cells kill extracellular *Pseudomonas aeruginosa* using contact-dependent release of granzymes B and H. *PLoS Pathog* 2022;18:e1010325.
19. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med* 2022;28:325-332.

20. Gee G, Sheridan S, Charles L, Dayne L, Joyce L, Stevens J, Paradies Y, Hulbert C, Haslam N, Thorpe R, Thorpe L, Thorpe A, Stewart P, Austin L, Lyons L, Belfrage M, Warber R, Paxton A, Thompson L. The Her Tribe and His Tribe Aboriginal-Designed Empowerment Programs. *Int J Environ Res Public Health* 2022;19:2381.
21. Goh PK, Wiede F, Zeissig MN, Britt KL, Liang S, Molloy T, Goode N, Xu R, Loi S, Muller M, Humbert PO, McLean C, Tiganis T. PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancer. *Sci Adv* 2022;8:eabk3338.
22. Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoune N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. *Eur J Cancer* 2022;162:22-33.
23. Gregory G, Das Gupta K, Meiser B, Barlow-Stewart K, Geelan-Small P, Kaur R, Scheepers-Joynt M, McInerney S, Taylor S, Antill Y, Salmon L, Smyth C, Young MA, James PA, Yanes T. Polygenic risk in familial breast cancer: Changing the dynamics of communicating genetic risk. *J Genet Couns* 2022;31:120-129.
24. Hoskins C, Tutty E, Purvis R, Shanahan M, Boussioutas A, Forrest L. Young people's experiences of a CDH1 pathogenic variant: Decision-making about gastric cancer risk management. *J Genet Couns* 2022;31:242-251.
25. Huang JY, Steele P, Dabscheck E, Smallwood N. Nasal High Flow Therapy For Symptom Management in People Receiving Palliative Care. *J Pain Symptom Manage* 2022;63:e237-e245.
26. Ivanova ME, Lukoyanova N, Malhotra S, Topf M, Trapani JA, Voskoboinik I, Saibil HR. The pore conformation of lymphocyte perforin. *Sci Adv* 2022;8:eabk3147.
27. Kader T, Zethoven M, Gorringer KL. Evaluating statistical approaches to define clonal origin of tumours using bulk DNA sequencing: context is everything. *Genome Biol* 2022;23:43.
28. Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suci S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Prognostic and predictive value of  $\beta$ -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. *Eur J Cancer* 2022;165:97-112.
29. Khaw P, Do V, Lim K, Cunningham J, Dixon J, Vassie J, Bailey M, Johnson C, Kahl K, Gordon C, Cook O, Foo K, Fyles A, Powell M, Haie-Meder C, D'Amico R, Bessette P, Mileshkin L, Creutzberg CL, Moore A. Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial. *Clin Oncol* 2022;34:198-204.
30. Kim SY, Kissane DW, Richardson G, Senior J, Morgan J, Gregory P, Birks S, Ooi C, Lipton L, Antill Y, Vereker M, Michael N, Bobevski I. The role of depression and other psychological factors in work ability among breast cancer survivors in Australia. *Psychooncology* 2022;31:167-175.
31. Kwok MM, Virk JS, Michael M, McKinley M, Magarey MJR. Cervical Nodal Metastatic Pituitary Carcinoma: A Case Report. *Ear Nose Throat J* 2022;101:110-113.
32. Larach JT, Flynn J, Wright T, Rajkomar AKS, McCormick JJ, Kong J, Smart PJ, Heriot AG, Warriar SK. Robotic complete mesocolic excision versus conventional robotic right colectomy for right-sided colon cancer: a comparative study of perioperative outcomes. *Surg Endosc* 2022;36:2113-20.
33. Lawrentschuk N. Editorial Comment. *J Urol* 2022;207:580.

34. Le BH, Aggarwal G, Douglas C, Green M, Nicoll A, Ahmedzai S. Oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe, chronic cancer pain: Challenges in the context of hepatic impairment. *Asia Pac J Clin Oncol* 2022;18:13-18.
35. Lickliter JD, Voskoboynik M, Mileshekin L, Gan HK, Kichenadasse G, Zhang K, Zhang M, Tang Z, Millward M. Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. *Br J Cancer* 2022;126:576-85.
36. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Munoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All ZUMA-7 Investigators, Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. *N Engl J Med* 2022;386:640-54.
37. MacManus M, Hegi-Johnson F. Overcoming immunotherapy resistance in NSCLC. *Lancet Oncol* 2022;23:191-3.
38. Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, MacPherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. *Eur J Cancer* 2022;164:39-51.
39. Mascarenhas J, Passamonti F, Burbury K, El-Galaly TC, Gerds A, Gupta V, Higgins B, Wonde K, Jamois C, Kovic B, Huw LY, Katakam S, Maffioli M, Mesa R, Palmer J, Bellini M, Ross DM, Vannucchi AM, Yacoub A. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. *Blood Adv* 2022;6:1162-74.
40. Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). *Clin Cancer Res* 2022;28:603-8.
41. Mazariego C, Jefford M, Chan RJ, Roberts N, Millar L, Anazodo A, Hayes S, Brown B, Saunders C, Webber K, Vardy J, Girgis A, Koczwara B, COSA PRO Working Group. Priority recommendations for the implementation of patient-reported outcomes in clinical cancer care: a Delphi study. *J Cancer Surviv* 2022;16:33-43.
42. McDowell L, Bossi P. The Burning Question: Prophylactic Gabapentin for Mucositis-Related Pain in Patients Undergoing Chemoradiation Therapy for Head and Neck Cancer? *Int J Radiat Oncol Biol Phys* 2022;112:938-41.
43. McDowell L, Rischin D, Gough K, Henson C. Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer. *Front Oncol* 2022;12:834068.
44. Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. *Cancer Discov* 2022;12:402-415.
45. Miles LF, Soo VP, Braat S, Heritier S, Burbury KL, Story DA. A protocol for prospective observational study to determine if non-anaemic iron deficiency worsens postoperative outcome in adult patients undergoing elective cardiac surgery: the IDOCS study. *Perioper Med* 2022;11:4.
46. Mohan H, Larach JT, Suhardja T, Wang J, Lawrentschuk N, Heriot A, Warriar S. Robotic ultralow anterior resection, en bloc hysterectomy, unilateral ureterectomy and pelvic side wall clearance with selective anterior internal iliac artery resection - A video vignette. *Colorectal Dis* 2022;24:243.

47. Nan Tie E, Kok DL. Merkel cell carcinoma: is sentinel lymph node biopsy crucial? *Intern Med J* 2022;52:330-331.
48. Nedumannil R, Juneja S. Large granular lymphocytosis: A novel association with immunotherapy. *Hematol Oncol* 2022;40:119-121.
49. O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH Jr, Safra T, Italiano A, Mileskin L, Xu L, Jin F, Norwood K, Maio M. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. *J Clin Oncol* 2022;40:752-61.
50. Ong WL, Milne RL, Foroudi F, Millar JL. Changing pattern of radiation therapy for bone metastases in an Australian population-based cohort of men with prostate cancer. *Clin Genitourin Cancer* 2022;20:e7-e15.
51. Parker A, Dash S, Bourke M, Patten R, Craike M, Baldwin P, Hosking W, Levinger I, Apostolopoulos V, de Courten M, Sharples J, Naslund M, Stavropoulos V, Woessner M, Sonn C, Stansen C, Pascoe M. A Brief, Daily, Online Mental Health and Well-being Intervention for University Staff During the COVID-19 Pandemic: Program Description and Outcomes Using a Mixed Methods Design. *JMIR Form Res* 2022;6:e35776.
52. Pearson EJ. Fatigue - a substantial problem in hematology, but what can be done? *Leuk Lymphoma* 2022;63:263-264.
53. Peters S, Thompson BA, Perrin M, James P, Zentner D, Kalman JM, Vandenberg JI, Fatkin D. Arrhythmic Phenotypes Are a Defining Feature of Dilated Cardiomyopathy-Associated *SCN5A* Variants: A Systematic Review. *Circ Genom Precis Med* 2022;15:e003432.
54. Rambhatla JS, Tonkin-Hill GQ, Takashima E, Tsuboi T, Noviyanti R, Trianty L, Sebayang BF, Lampah DA, Marfurt J, Price RN, Anstey NM, Papenfuss AT, Damelang T, Chung AW, Duffy MF, Rogerson SJ. Identifying Targets of Protective Antibodies against Severe Malaria in Papua, Indonesia, Using Locally Expressed Domains of Plasmodium falciparum Erythrocyte Membrane Protein 1. *Infect Immun* 2022;90:e0043521.
55. Rechtman M, Forbes A, Millar JL, Evans M, Dodds L, Murphy DG, Evans SM. Comparison of urinary and sexual patient-reported outcomes between open radical prostatectomy and robot-assisted radical prostatectomy: a propensity score matched, population-based study in Victoria. *BMC Urol* 2022;22:18.
56. Rowlands CF, Taylor A, Rice G, Whiffin N, Hall HN, Newman WG, Black GCM, kConFab Investigators, O'Keefe RT, Hubbard S, Douglas AGL, Baralle D, Briggs TA, Ellingford JM. MRSD: A quantitative approach for assessing suitability of RNA-seq in the investigation of mis-splicing in Mendelian disease. *Am J Hum Genet* 2022;109:210-22.
57. Sexton A, James PA. Metaphors and why these are important in all aspects of genetic counseling. *J Genet Couns* 2022;31:34-40.
58. Seymour JF. Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i. *Blood Adv* 2022;6:1365-70.
59. Solomon BJ, Loong HH, Summers Y, Thomas ZM, French P, Lin BK, Sashegyi A, Wolf J, Yang JC, Drilon A. Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. *ESMO Open* 2022;7:100398.
60. Subhash VV, Huang L, Kamili A, Wong M, Chen D, Venn NC, Atkinson C, Mayoh C, Venkat P, Tyrrell V, Marshall GM, Cowley MJ, Ekert PG, Norris MD, Haber M, Henderson MJ, Sutton R, Fletcher JJ, Trahair TN. Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. *Br J Cancer* 2022;126:482-491.

61. Tai A, Prakash S, Lade S, McCormack CJ, Goh MSY. Two cases of acquired perforating dermatosis successfully treated with allopurinol. *Australas J Dermatol* 2022;63:121-124.
62. Tam CS, Dimopoulos M, Garcia-Sanz R, Trotman J, Opat S, Roberts AW, Owen R, Song Y, Xu W, Zhu J, Li J, Qiu L, D'Sa S, Jurczak W, Cull G, Marlton P, Gottlieb D, Munoz J, Phillips T, Du C, Ji M, Zhou L, Guo H, Zhu H, Chan WY, Cohen A, Novotny W, Huang J, Tedeschi A. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. *Blood Adv* 2022;6:1296-308.
63. Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A, Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Survival with Cemiplimab in Recurrent Cervical Cancer. *N Engl J Med* 2022;386:544-55.
64. Trubiano JA, Vogrin S, Copaescu A, Nasra M, Douglas A, Holmes NE, Chua KYL. Direct oral penicillin challenge for penicillin allergy delabeling as a health services intervention: A multicenter cohort study. *Allergy* 2022;77:1038-42.

## March

1. Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghoul F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. *Future Oncol* 2022;18:1185-98.
2. Albarakati H, Jackson P, Gulal O, Ramachandran P, Osbourne G, Liu M, Kron T, Geso M. Dose assessment for daily cone-beam CT in lung radiotherapy patients and its combination with treatment planning. *Phys Eng Sci Med* 2022;45:231-7.
3. Arber DA, Hasserjian RP, Orazi A, Mathews V, Roberts AW, Schiffer CA, Roug AS, Cazzola M, Döhner H, Tefferi A. Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. *Am J Hematol* 2022;97:514-8.
4. Asfia A, Deepak B, Novak JJ, Rolfe B, Kron T. Multi-jet fusion for additive manufacturing of radiotherapy immobilization devices: Effects of color, thickness, and orientation on surface dose and tensile strength. *J Appl Clin Med Phys* 2022;23:e13548.
5. Aung E, Pasanen L, LeGautier R, McLachlan SA, Collins A, Philip J. The role of telehealth in oncology care: A qualitative exploration of patient and clinician perspectives. *Eur J Cancer Care* 2022;31:e13563.
6. Bandala-Sanchez E, Roth-Schulze AJ, Oakey H, Penno MAS, Bediaga NG, Naselli G, Ngui KM, Smith AD, Huang D, Zozaya-Valdes E, Thomson RL, Brown JD, Vuillermin PJ, Barry SC, Craig ME, Rawlinson WD, Davis EA, Harris M, Soldatos G, Colman PG, Wentworth JM, Haynes A, Morahan G, Sinnott RO, Papenfuss AT, Couper JJ, Harrison LC, ENDIA Study Group. Women with type 1 diabetes exhibit a progressive increase in gut *Saccharomyces cerevisiae* in pregnancy associated with evidence of gut inflammation. *Diabetes Res Clin Pract* 2022;184:109189.
7. Bean HR, Diggins J, Ftanou M, Alexander M, Stafford L, Bei B, Francis PA, Wiley JF. Light enhanced cognitive behavioral therapy for insomnia and fatigue during chemotherapy for breast cancer: a randomized controlled trial. *Sleep* 2022;45:zsab246.
8. Bensley JG, Dhillon HM, Evans SM, Evans M, Bolton D, Davis ID, Dodds L, Frydenberg M, Kearns P, Lawrentschuk N, Murphy DG, Millar JL, Papa N. Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registry. *Psychooncology* 2022;31:496-503.

9. Bergin ART. Insights into the Demands on a Clinical Oncologist in Sri Lanka. *JCO Glob Oncol* 2022;8:e2100429.
10. Bishop E, Miller C, Miller S, McKellar C. How staying in a single room affects the experiences of haematology inpatients in an Australian cancer hospital. *Br J Nurs* 2022;31:S22-S29.
11. Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD, Wei AH, Hayslip J, Miles D, Mensing S, Gopalakrishnan S, Zha J. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. *Hematol Oncol* 2022;40:269-79.
12. Breast Cancer Association Consortium, Mavaddat N, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Keeman R, Bolla MK, Dennis J, Wang Q, Ahearn TU, Andrulis IL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Briceno I, Bruning T, Camp NJ, Campbell A, Castela J, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Christiansen H, Czene K, Dork T, Eriksson M, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, Geisler J, Giles GG, Guenel P, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Hartikainen JM, Hartman M, Hoppe R, Howell A, Jakubowska A, Jung A, Khusnutdinova EK, Kristensen VN, Li J, Lim SH, Lindblom A, Loizidou MA, Lophatananon A, Lubinski J, Madsen MJ, Mannermaa A, Manoochehri M, Margolin S, Mavroudis D, Milne RL, Mohd Taib NA, Morra A, Muir K, Obi N, Osorio A, Park-Simon TW, Peterlongo P, Radice P, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Sim X, Southey MC, Thorne H, Tomlinson I, Torres D, Truong T, Yip CH, Spurdle AB, Vreeswijk MPG, Dunning AM, Garcia-Closas M, Pharoah PDP, Kvist A, Muranen TA, Nevanlinna H, Teo SH, Devilee P, Schmidt MK, Easton DF. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. *JAMA Oncol* 2022;8:e216744.
13. Busch K, Davidson A, Di Ieva A, Assaad N, Butlin M, Avolio A, Kiat H. Significant venous flow alterations following brain arteriovenous malformation Surgery: Assessment by transcranial colour duplex. *J Clin Neurosci* 2022;99:268-74.
14. Castiblanco D, Rudd-Schmidt JA, Noori T, Sutton VR, Hung YH, Flinsenberg TWH, Hodel AW, Young ND, Smith N, Bratkovic D, Peters H, Walterfang M, Trapani JA, Brennan AJ, Voskoboinik I. Severely impaired CTL killing is a feature of the neurological disorder Niemann-Pick disease type C1. *Blood* 2022;139:1833-49.
15. Chan RJ, Agbejule OA, Yates PM, Emery J, Jefford M, Koczwara B, Hart NH, Crichton M, Nekhlyudov L. Outcomes of cancer survivorship education and training for primary care providers: a systematic review. *J Cancer Surviv* 2022;16:279-302.
16. Chang D, Moore A, van Dyk S, Khaw P. Why quality assurance is necessary in gynecologic radiation oncology. *Int J Gynecol Cancer*. 2022;32:402-406.
17. Chee L, Ritchie D, Ludford-Menting M, Ripley J, Chung J, Park D, Norton S, Kenealy M, Koldej R. Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS). *Eur J Haematol* 2022;108:342-53.
18. Chic N, Luen SJ, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, Wang Y, de Azambuja E, Láng I, Di Cosimo S, Saura C, Huober J, Prat A, Loi S. Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. *J Natl Cancer Inst* 2022;114:467-70.
19. Cohen PA, Webb PM, King M, Obermair A, GebSKI V, Butow P, Morton R, Lawson W, Yates P, Campbell R, Meniawy T, McMullen M, Dean A, Goh J, McNally O, Mileskin L, Beale P, Beach R, Hill J, Dixon C, Hegarty S, Codde J, Ives A, Lee YC, Brand A, Mellon A, Bilic S, Black I, Jeffares S, Friedlander M. Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer. *Int J Gynecol Cancer* 2022;32:560-5.

20. Comberlato A, Koga MM, Nüssing S, Parish IA, Bastings MMC. Spatially Controlled Activation of Toll-like Receptor 9 with DNA-Based Nanomaterials. *Nano Lett* 2022;22:2506-13.
21. Crawford-Williams F, Koczwara B, Chan RJ, Vardy J, Lisy K, Morris J, Iddawela M, Mackay G, Jefford M. Defining research and infrastructure priorities for cancer survivorship in Australia: a modified Delphi study. *Support Care Cancer* 2022;30:3805-15.
22. Dall GV, Hamilton A, Ratnayake G, Scott C, Barker H. Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit. *Cancers* 2022;14:1561.
23. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmana J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, GEMO Study Collaborators, GC-HBOC Study Collaborators, EMBRACE Collaborators, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dork T, du Bois A, Durst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, OPAL Study Group, AOCs Group, Hahnen E, Haiman CA, Hakansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Hogdall E, Hogdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Investigators KC, Investigators H, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeny LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubinski J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT, Pathak H, Pedersen IS, Peixoto A, Pejovic T, Perez-Segura P, Permeth JB, Peshkin B, Peterlongo P, Piskorz A, Prokofyeva D, Radice P, Rantala J, Riggan MJ, Risch HA, Rodriguez-Antona C, Ross E, Rossing MA, Runnebaum I, Sandler DP, Santamarina M, Soucy P, Schmutzler RK, Setiawan VW, Shan K, Sieh W, Simard J, Singer CF, Sokolenko AP, Song H, Southey MC, Steed H, Stoppa-Lyonnet D, Sutphen R, Swerdlow AJ, Tan YY, Teixeira MR, Teo SH, Terry KL, Terry MB, Consortium O, Consortium C, Thomassen M, Thompson PJ, Thomsen LCV, Thull DL, Tischkowitz M, Titus L, Toland AE, Torres D, Trabert B, Travis R, Tung N, Tworoger SS, Valen E, van Altena AM, van der Hout AH, Van Nieuwenhuysen E, van Rensburg EJ, Vega A, Edwards DV, Vierkant RA, Wang F, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, White E, Whittemore AS, Winham SJ, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Zavaglia KM, Zheng W, Ziogas A, Zorn KK, Kleibl Z, Easton D, Lawrenson K, DeFazio A, Sellers TA, Ramus SJ, Pearce CL, Monteiro AN, Cunningham J, Goode EL, Schildkraut JM, Berchuck A, Chenevix-Trench G, Gayther SA, Antoniou AC, Pharoah PDP. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. *Eur J Hum Genet* 2022;30:349-62.
24. Dark C, Cheung S, Cheng LY. Analyzing cachectic phenotypes in the muscle and fat body of *Drosophila* larvae. *STAR Protoc* 2022;3:101230.
25. Davies A, Mathur N, Lau T, Crossett M, Lau KK. Venous air embolism in CT coronary angiography. *J Med Imaging Radiat Oncol* 2022;66:351-6.
26. Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. *Clin Cancer Res* 2022;28:1302-12.

27. Doig KD, Fellowes A, Scott P, Fox SB. Tumour mutational burden: an overview for pathologists. *Pathology* 2022;54:249-53.
28. Doig KD, Love CG, Conway T, Seleznev A, Ma D, Fellowes A, Blombery P, Fox SB. Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics. *BMC Med Genomics* 2022;15:70.
29. Dromain C, Vullierme MP, Hicks RJ, Prasad V, O'Toole D, de Herder WW, Pavel M, Faggiano A, Kos-Kudla B, Öberg K, Krejs GJ, Grande E, Niederle B, Sundin A. ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. *J Neuroendocrinol* 2022;34:e13044.
30. Du X, Darcy PK, Wiede F, Tiganis T. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors. *Mol Cell Biol* 2022;42:e0044921.
31. Dunn J, McCuaig RD, Tan AHY, Tu WJ, Wu F, Wagstaff KM, Zafar A, Ali S, Diwakar H, Dahlstrom JE, Bean EG, Forwood JK, Tsimbalyuk S, Cross EM, Hardy K, Bain AL, Ahern E, Dolcetti R, Mazziere R, Yip D, Eastgate M, Malik L, Milburn P, Jans DA, Rao S. Selective Targeting of Protein Kinase C (PKC)- $\theta$  Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers. *Cancers* 2022;14:1596.
32. Finnegan RN, Reynolds HM, Ebert MA, Sun Y, Holloway L, Sykes JR, Dowling J, Mitchell C, Williams SG, Murphy DG, Haworth A. A statistical, voxelised model of prostate cancer for biologically optimised radiotherapy. *Phys Imaging Radiat Oncol* 2022;21:136-45.
33. Foo T, Goldstein D, Segelov E, Shapiro J, Pavlakis N, Desai J, Yip D, Zalcborg J, Price TJ, Nagrial A, Chantrill L, Burge M, Karapetis CS, Tebbutt N, Roy AC. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. *Target Oncol* 2022;17:95-110.
34. Fortuno C, McGoldrick K, Pesaran T, Dolinsky J, Hoang L, Weitzel JN, Beshay V, San Leong H, James PA, Spurdle AB. Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity. *Genet Med* 2022;24:673-680.
35. Freifeld Y, Pedrosa I, McLaughlin M, Correa RM, Louie AV, Maldonado JA, Tang C, Kadow B, Kutikov A, Uzzo RG, Porta C, Bucknell NW, Siva S, Brugarolas J, Margulis V, Timmerman R, Hannan R. Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. *Urol Oncol* 2022;40:166.e9-166.e13.
36. Gambell P, Rowley G, Pham TAT, Dang TL, Mulumba H, Smith L, Lakos G. Accurate white blood cell differential by Alinity hq: A comparison with flow cytometry and manual differential. *Int J Lab Hematol* 2022;44:288-95.
37. Garciaz S, Guirguis AA, Müller S, Brown FC, Chan YC, Motazedian A, Rowe CL, Kuzich JA, Chan KL, Tran K, Smith L, MacPherson L, Liddicoat B, Lam EYN, Cañeque T, Burr ML, Litalien V, Pomilio G, Poplineau M, Duprez E, Dawson SJ, Ramm G, Cox AG, Brown KK, Huang DCS, Wei AH, McArthur K, Rodriguez R, Dawson MA. Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. *Cancer Discov* 2022;12:774-791.
38. Gasperoni JG, Fuller JN, Darido C, Wilanowski T, Dworkin S. Grainyhead-like (Grhl) Target Genes in Development and Cancer. *Int J Mol Sci* 2022;23:2735.
39. Gelber RD, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. *Eur J Cancer* 2022;166:219-28.
40. Gill JG, Leef SN, Ramesh V, Martin-Sandoval MS, Rao AD, West L, Muh S, Gu W, Zhao Z, Hosler GA, Vandergriff TW, Durham AB, Mathews TP, Aurora AB. A Short Isoform of Spermatogenic Enzyme GAPDHS Functions as a Metabolic Switch and Limits Metastasis in Melanoma. *Cancer Res* 2022;82:1251-66.



41. Goh Y, Kim D, Kim JY, Kim HS, Jeong JH, Lee SU, Youn SH, Oh ES, Ha BR, Yeo AU, Kim M, Shin D, Lee SB, Kim YJ, Kim TH, Lim YK. Active small bowel sparing in intracavitary brachytherapy for cervical cancer. *Jpn J Clin Oncol* 2022;52:266-73.
42. Gondoputro W, Thompson J, Evans M, Bolton D, Frydenberg M, Murphy DG, Haynes AM, Agrawal S, Stricker P, Papa N. How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires. *J Urol* 2022;207:1048-56.
43. Gough K, Pascoe MC, Bergin R, Drosdowsky A, Schofield P. Differential adherence to peer and nurse components of a supportive care package—The appeal of peer support may be related to women's health and psychological status. *Patient Educ Couns* 2022;105:762-768.
44. Grobler AC, Lee KJ, Wong A, Currow DC, Braat S. Handling Missing Data and Drop Out in Hospice/Palliative Care Trials Through the Estimand Framework. *J Pain Symptom Manage* 2022;63:e431-9.
45. Hardcastle N, Hughes J, Siva S, Kron T. Dose calculation and reporting with a linear Boltzman transport equation solver in vertebral SABR. *Phys Eng Sci Med* 2022;45:43-48.
46. Harden SV, Chiew KL, Millar J, Vinod SK. Quality indicators for radiation oncology. *J Med Imaging Radiat Oncol* 2022;66:249-257.
47. Hatten SJ Jr, Lehrer EJ, Liao J, Sha CM, Trifiletti DM, Siva S, McBride SM, Palma D, Holder SL, Zaorsky NG. A Patient-Level Data Meta-analysis of the Abscopal Effect. *Adv Radiat Oncol* 2022;7:100909.
48. Heazlewood SY, Ahmad T, Mohenska M, Guo BB, Gangatirkar P, Josefsson EC, Ellis SL, Ratnadiwakara M, Cao H, Cao B, Heazlewood CK, Williams B, Fulton M, White JF, Ramialison M, Nilsson SK, Änkö ML. The RNA-binding protein SRSF3 has an essential role in megakaryocyte maturation and platelet production. *Blood* 2022;139:1359-73.
49. Hegarty S, Hardcastle N, Korte J, Kron T, Everitt S, Rahim S, Hegi-Johnson F, Franich R. Please Place Your Seat in the Full Upright Position: A Technical Framework for Landing Upright Radiation Therapy in the 21<sup>st</sup> Century. *Front Oncol* 2022;12:821887.
50. Hegi-Johnson F, Rudd S, Hicks RJ, De Ruyscher D, Trapani JA, John T, Donnelly P, Blyth B, Hanna G, Everitt S, Roselt P, MacManus MP. Imaging immunity in patients with cancer using positron emission tomography. *NPJ Precis Oncol* 2022;6:24.
51. Heinze K, Nazeran TM, Lee S, Krämer P, Cairns ES, Chiu DS, Leung SC, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommos F, Vollert HW, Heitz F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, Kommos FK, Heublein S, Sinn HP, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Tołoczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Gorringer KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon U, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PD, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee CH, Goode EL, Nelson BH, Ramus SJ, Kommos S, Talhouk A, Köbel M, Anglesio MS. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. *J Pathol* 2022;256:388-401.
52. Heitink L, Whittle JR, Vaillant F, Capaldo BD, Dekkers JF, Dawson CA, Milevskiy MJG, Surgenor E, Tsai M, Chen HR, Christie M, Chen Y, Smyth GK, Herold MJ, Strasser A, Lindeman GJ, Visvader JE. In vivo genome-editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis. *Mol Oncol* 2022;16:1119-31.
53. Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O'Toole D, Sundin A,

Prasad V. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. *J Neuroendocrinol* 2022;34:e13040.

54. Holliday H, Yang J, Dodson E, Nikolic I, Kamili A, Wheatley M, Deng N, Alexandrou S, Davis TP, Kavallaris M, Caldon CE, McCarroll J, De Preter K, Mestdagh P, Marshall GM, Simpson KJ, Fletcher J, Swarbrick A. miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma. *Mol Ther* 2022;30:1119-34.
55. Horeweg N, Workel HH, Loiero D, Church DN, Vermij L, Léon-Castillo A, Krog RT, de Boer SM, Nout RA, Powell ME, Mileskin LR, MacKay H, Leary A, Singh N, Jürgenliemk-Schulz IM, Smit V, Creutzberg CL, Koelzer VH, Nijman HW, Bosse T, de Bruyn M. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. *Nat Commun* 2022;13:1373.
56. Hübner M, Alyami M, Villeneuve L, Cortés-Guiral D, Nowacki M, So J, Sgarbura O. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. *Eur J Surg Oncol* 2022;48:789-94.
57. Ierano C, Rajkhowa A, Gotterson F, Marshall C, Peel T, Ayton D, Thursky K. Opportunities for nurse involvement in surgical antimicrobial stewardship strategies: A qualitative study. *Int J Nurs Stud* 2022;128:104186.
58. Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi Kumar A. Radiation Dosimetry in <sup>177</sup>Lu-PSMA-617 Therapy. *Semin Nucl Med* 2022;52:243-54.
59. Jackson TD, Cramer JJ, Muellner-Wong L, Frazier AE, Palmer CS, Formosa LE, Hock DH, Fujihara KM, Stait T, Sharpe AJ, Thorburn DR, Ryan MT, Stroud DA, Stojanovski D. Sideroflexin 4 is a complex I assembly factor that interacts with the MCIA complex and is required for the assembly of the ND2 module. *Proc Natl Acad Sci USA* 2022;119:e2115566119.
60. Jalali A, Gard G, Banks S, Dunn C, Wong HL, Wong R, Lee M, Gately L, Loft M, Shapiro JD, Kosmider S, Tie J, Ananda S, Yeung JM, Jennens R, Lee B, McKendrick J, Lim L, Khattak A, Gibbs P. Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. *Curr Probl Cancer* 2022;46:100793.
61. Jepp CK, Foley DA, Chua IJ, Kwong JC, Payne MS, Davis J, Yeoh DK. Ureaplasma urealyticum meningitis complicated by hydrocephalus in a preterm neonate. *J Paediatr Child Health* 2022;58:529-531.
62. Jiang W, Lokuhetty N, Mohan HM, Larach JT, Waters P, Heriot AG, Warriar SK. How to do a robotic lateral pelvic side wall dissection for rectal cancer. *ANZ J Surg* 2022;92:540-2.
63. Johnson DN, Ruan Z, Petley EV, Devi S, Holz LE, Uldrich AP, Mak JYW, Hor JL, Mueller SN, McCluskey J, Fairlie DP, Darcy PK, Beavis PA, Heath WR, Godfrey DI. Differential location of NKT and MAIT cells within lymphoid tissue. *Sci Rep* 2022;12:4034.
64. Jones ME, Mohan HM, Rajkomar AKS, Larach JT, Warriar SK. Refining the art of the robotic TAMIS - A video vignette. *Colorectal Dis* 2022;24:339-340.
65. Kim S, Pitson G, Koh TL, Chao M, Byrne K, Hornby C, Foroudi F, Millar J, Ong WL. Increasing use of post-mastectomy hypofractionated radiation therapy for breast cancer in Victoria. *J Med Imaging Radiat Oncol* 2022;66:428-35.
66. Kolka CM, Webster J, Lepletier A, Winterford C, Brown I, Richards RS, Zelek WM, Cao Y, Khamis R, Shanmugasundaram KB, Wuethrich A, Trau M, Brosda S, Barbour A, Shah AK, Eslick GD, Clemons NJ, Morgan BP, Hill MM. C5b-9 Membrane Attack Complex Formation and Extracellular Vesicle Shedding in Barrett's Esophagus and Esophageal Adenocarcinoma. *Front Immunol* 2022;13:842023.
67. Koo K, Papa N, Evans M, Jefford M, Ilzerman M, White V, Evans SM, Ristevski E, Emery J, Millar J. Mapping disadvantage: identifying inequities in functional outcomes for prostate cancer survivors based on geography. *BMC Cancer* 2022;22:283.
68. Kron T. Cui Bono, Proton Radiotherapy? *Clin Oncol* 2022;34:258-60.

69. Kron T, Fox C, Ebert MA, Thwaites D. Quality management in radiotherapy treatment delivery. *J Med Imaging Radiat Oncol* 2022;66:279-290.
70. Kwan EM, Spain L, Anton A, Gan CL, Garrett L, Chang D, Liow E, Bennett C, Zheng T, Yu J, Dai C, Du P, Jia S, Fettke H, Abou-Seif C, Kothari G, Shaw M, Parente P, Pezaro C, Tran B, Siva S, Azad AA. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial. *Eur Urol* 2022;81:253-262.
71. Larkins KM, Soucisse ML, Larach JT, Heriot A, Warriar SK. Multidisciplinary management of rare cancers: Recurrent neuroendocrine carcinoma of the appendix. *ANZ J Surg* 2022;92:598-600.
72. Lasocki A, Seymour JF. Central nervous system manifestations of systemic haematological malignancies and key differentials. *Clin Radiol* 2022;77:328-36.
73. Lau LMS, Mayoh C, Xie J, Barahona P, MacKenzie KL, Wong M, Kamili A, Tsoli M, Failes TW, Kumar A, Mould EVA, Gifford A, Chow SO, Pinese M, Fletcher JI, Arndt GM, Khuong-Quang DA, Wadham C, Batey D, Eden G, Trebilcock P, Joshi S, Alfred S, Gopalakrishnan A, Khan A, Grebert Wade D, Strong PA, Manouvrier E, Morgan LT, Span M, Lim JY, Cadiz R, Ung C, Thomas DM, Tucker KM, Warby M, McCowage GB, Dalla-Pozza L, Byrne JA, Saletta F, Fellowes A, Fox SB, Norris MD, Tyrrell V, Trahair TN, Lock RB, Cowley MJ, Ekert PG, Haber M, Ziegler DS, Marshall GM. In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer. *EMBO Mol Med* 2022;14:e14608.
74. Lau SYC, Choy KT, Yang TWW, Heriot A, Warriar SK, Guest GD, Kong JC. Defining the learning curve of transanal total mesorectal excision: a systematic review and meta-analysis. *ANZ J Surg* 2022;92:355-364.
75. Lawther AJ, Phillips AJK, Chung NC, Chang A, Ziegler AI, Debs S, Sloan EK, Walker AK. Disrupting circadian rhythms promotes cancer-induced inflammation in mice. *Brain Behav Immun Health* 2022;21:100428.
76. Lo AC, James LP, Prica A, Raymakers A, Peacock S, Qu M, Louie AV, Savage KJ, Sehn LH, Hodgson D, Yang JC, Eich HTT, Wirth A, Hunink MGM. PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma. *J Nucl Med* 2022;63:543-8.
77. Lokuhetty N, Mohan HM, Kong JC, Heriot AG, Warriar SK. Lateral pelvic sidewall dissection in rectal cancer: case selection and training to optimize outcomes. *Br J Surg* 2022;109:306-7.
78. Mak B, Lin HM, Kwan EM, Fettke H, Tran B, Davis ID, Mahon K, Stockler MR, Briscoe K, Marx G, Zhang A, Crumbaker M, Tan W, Huynh K, Meikle TG, Mellett NA, Hoy AJ, Du P, Yu J, Jia S, Joshua AM, Waugh DJ, Butler LM, Kohli M, Meikle PJ, Azad AA, Horvath LG. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. *BMC Med* 2022;20:112.
79. Maleki S, Glewis S, Fua T, Liu C, Rischin D, Alexander M, Na L, Lingaratnam S. A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapy. *Support Care Cancer* 2022;30:4243-53.
80. McQuilten ZK, Busija L, Seymour JF, Stanworth S, Wood EM, Kenealy M, Weinkove R, Australasian Leukaemia and Lymphoma Group (ALLG). Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. *Leuk Lymphoma* 2022;63:676-683.
81. Meiser B, Woodward P, Gleeson M, Kentwell M, Fan HM, Antill Y, Butow PN, Boyle F, Best M, Taylor N, Bell K, Tucker K. Pilot study of an online training program to increase genetic literacy and communication skills in oncology healthcare professionals discussing BRCA1/2 genetic testing with breast and ovarian cancer patients. *Fam Cancer* 2022;21:157-66.
82. Mendis S, To YH, Tie J. Biomarkers in Locally Advanced Rectal Cancer: A Review. *Clin Colorectal Cancer* 2022;21:36-44.

83. Minson A, Tam C, Dickinson M, Seymour JF. Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas. *Cancers* 2022;14:1276.
84. Nedumannil R, Leitinger E, Juneja S. Extreme Thrombocytosis in Refractory ITP Post-Splenectomy with Associated Fatal Thromboembolism. *Clin Pathol* 2022;15:2632010x221083218.
85. Ng SP, Ngan SY, Leong T. Current State of Neoadjuvant Radiotherapy for Rectal Cancer. *Clin Colorectal Cancer* 2022;21:63-70.
86. Osong B, Masciocchi C, Damiani A, Bermejo I, Meldolesi E, Chiloiro G, Berbee M, Lee SH, Dekker A, Valentini V, Gerard JP, Rödel C, Bujko K, van de Velde C, Folkesson J, Sainato A, Glynne-Jones R, Ngan S, Brændengen M, Sebag-Montefiore D, van Soest J. Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery. *Phys Imaging Radiat Oncol* 2022;22:1-7.
87. Ou SI, Solomon BJ, Shaw AT, Gadgeel SM, Besse B, Soo RA, Abbattista A, Toffalorio F, Wiltshire R, Bearz A. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. *J Thorac Oncol* 2022;17:568-77.
88. Pathmanandavel S, Crumbaker M, Yam AO, Nguyen A, Rofe C, Hovey E, Gedye C, Kwan EM, Hauser C, Azad AA, Eu P, Martin AJ, Joshua AM, Emmett L. <sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. *J Nucl Med* 2022;63:560-6.
89. Philip J, Le B, Pasanen L, Rosens E, Wong A, Mendis R, Boughey M, Coperchini M, Moran J, Hynson J, Weil J, Rosenthal M. Palliative Care Clinical Trials: Building Capability and Capacity. *J Palliat Med* 2022;25(3):421-427.
90. Pirie K, Doane MA, Riedel B, Myles PS. Analgesia for major laparoscopic abdominal surgery: a randomised feasibility trial using intrathecal morphine. *Anaesthesia* 2022;77:428-37.
91. Prabakaran A, Koldej R, Chee L, Ritchie D. Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation. *Blood Adv* 2022;6:1947-59.
92. Prabhakaran S, Yang TWW, Johnson N, Bell S, Chin M, Simpson P, Carne P, Farmer C, Skinner S, Warriar SK, Kong JC. Latest evidence on the management of early-stage and locally advanced rectal cancer: a narrative review. *ANZ J Surg* 2022;92:365-72.
93. Prall OWJ, Browning J, Nasteviski V, Caporarello S, Bates B, Hewitt CA, Arenas A, Lamb G, Howlett K, Arnolda R, Adeloju R, Stuart S, Xu H, Fellowes A, Fox SB. ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance. *Pathology* 2022;54:279-85.
94. Rischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrris A, Braña I, Neupane P, Bratland Å, Fueterer T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Hong RL, Mendoza RG, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. *Oral Oncol* 2022;128:105815.
95. Runacres F, Steele P, Hudson J, Bills M, Poon P. 'We couldn't have managed without your team': A collaborative palliative care response to the COVID-19 pandemic in residential aged care. *Australas J Ageing* 2022;41:147-152.
96. Salem ME, El-Refai SM, Sha W, Puccini A, Grothey A, George TJ, Hwang JJ, O'Neil B, Barrett AS, Kadakia KC, Musselwhite LW, Raghavan D, Van Cutsem E, Tabernero J, Tie J. Landscape of *KRAS*<sup>G12C</sup>, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in *KRAS*-Mutated Cancers. *JCO Precis Oncol* 2022;6:e2100245.
97. Sapkaroski D, Mundy M, Dimmock MR. Immersive virtual reality simulated learning environment versus role-play for empathic clinical communication training. *J Med Radiat Sci* 2022;69:56-65.

98. Seidel C, Hentrich M, Zschabitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, Schwab C, Bokemeyer C, Oing C. Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). *World J Urol* 2022;40:355-61.
99. Singh J, Gorniak M, Grigoriadis G, Westerman D, McBean M, Venn N, Law T, Sutton R, Morgan S, Fleming S. Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia. *Cytometry B Clin Cytom* 2022;102:115-122.
100. Siva S, Ali M, Guckenberger M. Pre-emptive or reactive? PROMPT spinal screening in metastatic castration-resistant prostate cancer. *Lancet Oncol* 2022;23:443-4.
101. Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, Tran B, A AA, Lewin JH, Cuff KE, Liu HY, Moon D, Goad J, Wong LM, LimJoon M, Mooi J, Chander S, Murphy DG, Lawrentschuk N, Pryor D. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPOR Trial. *Eur Urol* 2022;81:364-72.
102. Siva S, Louie AV. Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma - buying time or time to change? *Nat Rev Urol* 2022;19:197-8.
103. Smith LK, Parmenter T, Kleinschmidt M, Kusnadi EP, Kang J, Martin CA, Lau P, Patel R, Lorent J, Papadopoli D, Trigou A, Ward T, Rao AD, Lelliott EJ, Sheppard KE, Goode D, Hicks RJ, Tiganis T, Simpson KJ, Larsson O, Blythe B, Cullinane C, Wickramasinghe VO, Pearson RB, McArthur GA. Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF<sup>V600</sup> melanoma. *Nat Commun* 2022;13:1100.
104. Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K, GALAHAD investigators. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. *Lancet Oncol* 2022;23:362-73.
105. Soh KT, Came N, Otteson GE, Jevremovic D, Shi M, Olteanu H, Natoni A, Lagoo A, Theakston E, Oskarsson J, Gorniak M, Grigoriadis G, Arroz M, Fletcher M, Lin P, Ludwig P, Tembhare P, Matuzeviciene R, Radzevicius M, Kay S, Chen W, Cabrita C, Wallace PK. Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis. *Cytometry B Clin Cytom* 2022;102:88-106.
106. Stockler MR, Martin AJ, Davis ID, Dhillon HM, Begbie SD, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter DG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ, ENZAMET Trial Investigators, Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. *J Clin Oncol* 2022;40:837-46.
107. Tabernero J, Andre F, Blay JY, Bustillos A, Fear S, Ganta S, Jaeger D, Maio M, Mileskin L, Melero I. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. *ESMO Open* 2022;7:100419.
108. Teh JSK, Coussement J, Neoh ZCF, Spelman T, Lazarakis S, Slavin MA, Teh BW. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. *Blood Adv* 2022;6:2014-34.
109. Thompson JR, Smith AL, Lo SN, Kasparian NA, Saw RP, Dieng M, Seaman L, Martin LK, Guitera P, Milne D, Schmid H, Cust AE, Bartula I. Protocol for the implementation of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (0-II) melanoma. *BMJ Open* 2022;12:e054337.

110. Tjokrowidjaja A, Lord SJ, John T, Lewis CR, Kok PS, Marschner IC, Lee CK. Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer. *Cancer* 2022;128:1574-83.
111. Tjong MC, Louie AV, Singh AK, Videtic G, Stephans K, Plumridge N, Harden S, Slotman BJ, Alongi F, Guckenberger M, Siva S. Single-Fraction Stereotactic Ablative Body Radiotherapy to the Lung - The Knockout Punch. *Clin Oncol* 2022;34:e183-94.
112. Tobar LE, Farnsworth RH, Stacker SA. Brain Vascular Microenvironments in Cancer Metastasis. *Biomolecules* 2022;12:401.
113. Tun Min S, Roohullah A, Tognela A, Jalali A, Lee M, Wong R, Shapiro J, Burge M, Yip D, Nott L, Zimet A, Lee B, Dean A, Steel S, Wong HL, Gibbs P, Lim SH. Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an Australian population. *Asia Pac J Clin Oncol* 2022;18:e56-e63.
114. Udovicich C, Ng SP, Tange D, Bailey N, Haghghi N. From Postoperative to Preoperative: A Case Series of Hypofractionated and Single-Fraction Neoadjuvant Stereotactic Radiosurgery for Brain Metastases. *Oper Neurosurg* 2022;22:208-14.
115. Vaidyanathan S, Salmi TM, Sathiqu RM, McConville MJ, Cox AG, Brown KK. YAP regulates an SGK1/mTORC1/SREBP-dependent lipogenic program to support proliferation and tissue growth. *Dev Cell* 2022;57:719-31.
116. van de Ven M, Ijzerman M, Retèl V, van Harten W, Koffijberg H. Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer. *BMC Med Res Methodol* 2022;22:83.
117. Vatandoust S, Wattchow D, Sposato L, Michael MZ, Leung J, Gormly K, Chen G, Symonds EL, Tie J, Papanicolaos LE, Woods S, Gebiski V, Mead K, Kuruni A, Karapetis CS. A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol. *BMC Cancer* 2022;22:222.
118. Vaz SC, Adam JA, Delgado Bolton RC, Vera P, van Elmpt W, Herrmann K, Hicks RJ, Lievens Y, Santos A, Schöder H, Dubray B, Visvikis D, Troost EGC, de Geus-Oei LF. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[<sup>18</sup>F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. *Eur J Nucl Med Mol Imaging* 2022;49:1386-1406.
119. Vaz SC, Adam JA, Delgado Bolton RC, Vera P, van Elmpt W, Herrmann K, Hicks RJ, Lievens Y, Santos A, Schöder H, Dubray B, Visvikis D, Troost EGC, de Geus-Oei LF. Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[<sup>18</sup>F]FDG-PET/CT external beam radiation treatment planning in lung cancer. *Radiother Oncol* 2022;168:37-39.
120. Walls GM, Osman SOS, Brown KH, Butterworth KT, Hanna GG, Hounsell AR, McGarry CK, Leijenaar RTH, Lambin P, Cole AJ, Jain S. Radiomics for Predicting Lung Cancer Outcomes Following Radiotherapy: A Systematic Review. *Clin Oncol* 2022;34:e107-e122.
121. Wang M, Zadeh S, Pizzolla A, Thia K, Gyorki DE, McArthur GA, Scolyer RA, Long G, Wilmott JS, Andrews MC, Au-Yeung G, Weppler A, Sandhu S, Trapani JA, Davis MJ, Neeson PJ. Characterization of the treatment-naïve immune microenvironment in melanoma with BRAF mutation. *J Immunother Cancer* 2022;10:e004095.
122. Watt AC, Goel S. Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. *Breast Cancer Res* 2022;24:17.
123. Weld-Blundell IV, Grech L, Learmonth YC, Marck CH. Lifestyle and complementary therapies in multiple sclerosis guidelines: Systematic review. *Acta Neurol Scand* 2022;145:379-92.
124. Wiede F, Lu KH, Du X, Zeissig MN, Xu R, Goh PK, Xirouchaki CE, Hogarth SJ, Greatorex S, Sek K, Daly RJ, Beavis PA, Darcy PK, Tonks NK, Tiganis T. PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. *Cancer Discov* 2022;12:752-773.

125. Xu JJ, Chalk AM, Nikolic I, Simpson KJ, Smeets MF, Walkley CR. Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation. *Blood Adv* 2022;6:2092-106.
126. Ye Z, Li S, Dite GS, Nguyen TL, MacInnis RJ, Andrulis IL, Buys SS, Daly MB, John EM, Kurian AW, Genkinger JM, Chung WK, Phillips KA, Thorne H, kConFab, Winship IM, Milne RL, Dugue PA, Southey MC, Giles GG, Terry MB, Hopper JL. Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). *Cancer Prev Res* 2022;15:185-91.
127. Yeoh ZH, Roberts AW. Acute leukaemia in Australia: outcomes have improved, but there is still much to do. *Med J Aust* 2022;216:289-90.

## April

1. Abo S, Parry SM, Ritchie D, Sgro G, Truong D, Denehy L, Granger CL. Exercise in allogeneic bone marrow transplantation: a qualitative representation of the patient perspective. *Support Care Cancer* 2022;30:5389-99.
2. Ahmed F, Tseng HY, Ahn A, Gunatilake D, Alavi S, Eccles M, Rizos H, Gallagher SJ, Tiffen JC, Hersey P, Emran AA. Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma. *J Invest Dermatol* 2022;142:1444-55.
3. Alese OB, Cook N, Ortega-Franco A, Ulanja MB, Tan L, Tie J. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. *Am Soc Clin Oncol Educ Book* 2022;42:1-20.
4. Balasubramanian A, John T, Asselin-Labat ML. Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance. *Biochem Soc Trans* 2022;50:825-37.
5. Beattie BJ, Akhurst TJ, Augensen F, Humm JL. SUVfdg: A standard-uptake-value (SUV) body habitus normalizer specific to fluorodeoxyglucose (FDG) in humans. *PLoS One* 2022;17:e0266704.
6. Bogdanovic B, Solari EL, Villagran Asiares A, McIntosh L, van Marwick S, Schachoff S, Nekolla SG. PET/MR Technology: Advancement and Challenges. *Semin Nucl Med* 2022;52:340-55.
7. Brims FJ, McWilliams A, Harden SV, O'Byrne K. Lung cancer: progress with prognosis and the changing state of play. *Med J Aust* 2022;216:334-6.
8. Brown LC, Loi S. Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update. *Breast* 2022;62:S29-S33.
9. Brown LM, Hediye-Zadeh S, Sadras T, Huckstep H, Sandow JJ, Bartolo RC, Kosasih HJ, Davidson NM, Schmidt B, Bjelosevic S, Johnstone R, Webb AI, Khaw SL, Oshlack A, Davis MJ, Ekert PG. SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia. *Blood Adv* 2022;6:2373-87.
10. Cole E, Huang D, Larach JT, Rajkomar A, Farmer KC, Warriar S. Robotic total pelvic exenteration with en bloc pelvic side wall clearance and internal iliac artery resection - A Video Vignette. *Colorectal Dis* 2022;24:537-538.
11. Conduit C, Mak B, Qu W, Lulio JD, Burder R, Bressel M, Cusick T, Dhillon HM, Lourenço RA, Underhill C, Torres J, Crumbaker M, Honeyball F, Linton A, Allen R, Davis ID, Clark SJ, Horvath LG, Mahon KL. GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol). *Ther Adv Med Oncol* 2022;14:17588359221092486.
12. Connolly EA, Bhadri VA, Wake J, Ingley KM, Lewin J, Bae S, Wong DD, Long AP, Pryor D, Thompson SR, Strach MC, Grimison PS, Mahar A, Bonar F, Maclean F, Hong A. Systemic treatments and outcomes in CIC-rearranged Sarcoma: A national multi-centre clinicopathological series and literature review. *Cancer Med* 2022;11:1805-16.

13. Cusack R, Bates A, Mitchell K, van Willigen Z, Denehy L, Hart N, Dushianthan A, Reading I, Chorozoglou M, Sturmev G, Davey I, Grocott M. Improving physical function of patients following intensive care unit admission (EMPRESS): protocol of a randomised controlled feasibility trial. *BMJ Open* 2022;12:e055285.
14. Dang TH, Forkan ARM, Wickramasinghe N, Jayaraman PP, Alexander M, Burbury K, Schofield P. Investigation of Intervention Solutions to Enhance Adherence to Oral Anticancer Medicines in Adults: Overview of Reviews. *JMIR Cancer* 2022;8:e34833.
15. Dickinson M. Challenges in the development of bispecific antibodies for non-Hodgkin lymphoma. *Lancet Haematol* 2022;9:e314-15.
16. Dix-Matthews A, Palladino M, Lim S, McLeod C, Blyth CC, Yeoh DK. Rare cause of scalp swelling in an infant. *J Paediatr Child Health* 2022;58:730-731.
17. Drewett GP, Smibert OC, Holmes NE, Trubiano JA. The use of procalcitonin as an antimicrobial stewardship tool and a predictor of disease severity in coronavirus disease 2019 (COVID-19). *Infect Control Hosp Epidemiol* 2022;43:542-543.
18. Ekanayake Weeramange C, Shu D, Tang KD, Batra J, Ladwa R, Kenny L, Vasani S, Frazer IH, Dolcetti R, Ellis JJ, Sturm RA, Leo P, Punyadeera C. Analysis of human leukocyte antigen associations in human papillomavirus-positive and -negative head and neck cancer: Comparison with cervical cancer. *Cancer* 2022;128:1937-47.
19. Ellis JA, Malalasekera VS, Allan C, Choong PF, Hansford JR, Hehir R, Morello N, O'Callaghan S, Orme L, Phillipson N, Rosenthal MA, Sawyer S, Strong R, Super L, Watt A, Williams C, Woollett A, Robertson A, Lewin J. Systems-Level Change to Alleviate Barriers to Cancer Clinical Trial Access for Adolescents and Young Adults in Australia. *J Adolesc Young Adult Oncol* 2022;11:173-180.
20. Emery J, Butow P, Lai-Kwon J, Nekhlyudov L, Rynderman M, Jefford M. Management of common clinical problems experienced by survivors of cancer. *Lancet* 2022;399:1537-50.
21. Galgano SJ, Irvani A, Bodei L, El-Haddad G, Hofman MS, Kong G. Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-AJR Expert Panel Narrative Review. *AJR Am J Roentgenol* 2022;218:767-80.
22. Gao J, Jung M, Williams RT, Hui D, Russell AJ, Naim AJ, Kamili A, Clifton M, Bongers A, Mayoh C, Ho G, Scott CL, Jessup W, Haber M, Norris MD, Henderson MJ, Australian Ovarian Cancer Study. Suppression of the ABCA1 Cholesterol Transporter Impairs the Growth and Migration of Epithelial Ovarian Cancer. *Cancers* 2022;14:1878.
23. Gaudreault M, Chang D, Hardcastle N, Jackson P, Kron T, Hanna GG, Hofman MS, Siva S. Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer. *Front Oncol* 2022;12:854589.
24. Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N, Kolinsky MP, Roubaud G, Özgüroğlu M, Matsubara N, Gedye C, Choi YD, Padua C, Kohlmann A, Huisden R, Elvin JA, Kang J, Adelman CA, Allen A, Poehlein C, de Bono J. Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). *Clin Cancer Res* 2022;28:1518-30.
25. Iyengar KP, Azzopardi C, Kiernan G, Botchu R. Isolated pathologies of Tensor Fasciae Latae: Retrospective cohort analysis from a tertiary referral centre. *J Clin Orthop Trauma* 2022;29:101870.
26. Jefford M, Howell D, Li Q, Lisy K, Maher J, Alfano CM, Rynderman M, Emery J. Improved models of care for cancer survivors. *Lancet* 2022;399:1551-60.
27. Jobson D, McCormack CJ, Mar V, Tam C, Henderson MA. Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study. *Br J Haematol* 2022;197:320-5.
28. Jones ME, Stokes M, Warriar SK. Laparoscopic repair of coccygeal hernia with biological mesh following partial coccygectomy. *ANZ J Surg* 2022;92:912-914.



29. Katz NT, Jones J, Mansfield L, Gold M. The Impact of Health Professionals' Language on Patient Experience: A Case Study. *J Patient Exp* 2022;9:23743735221092572.
30. Kiss N, Steer B, de van der Schueren M, Loeliger J, Alizadehsani R, Edbrooke L, Deftereos I, Laing E, Khosravi A. Comparison of the prevalence of 21 GLIM phenotypic and etiologic criteria combinations and association with 30-day outcomes in people with cancer: A retrospective observational study. *Clin Nutr* 2022;41:1102-11.
31. Koulis A, Di Costanzo N, Mitchell C, Lade S, Goode D, Busuttill RA, Boussioutas A. CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric intestinal metaplasia. *BMC Gastroenterol* 2022;22:197.
32. Kulasekararaj A, Glasmacher A, Liu P, Szer J, Araten D, Rauch G, Gwaltney C, Sierra JR, Lee JW. Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria. *Eur J Haematol* 2022;108:391-402.
33. Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. *N Engl J Med* 2022;386:1421-31.
34. Kwok MMK, Choong KWK, Virk J, Kleid S, Magarey MJR. Lateral temporal bone resections for peri-auricular cutaneous squamous cell carcinoma: prognostic indicators and radiological predictive values. *J Laryngol Otol* 2022;136:297-303.
35. Lee K, Le T, Hau E, Hanna GG, Gee H, Vinod S, Dammak S, Palma D, Ong A, Yeghiaian-Alvandi R, Buck J, Lim R. A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC). *Int J Radiat Oncol Biol Phys* 2022;113:40-59.
36. Lehmann J, Hussein M, Barry MA, Siva S, Moore A, Chu M, Díez P, Eaton DJ, Harwood J, Lonski P, Claridge Mackonis E, Meehan C, Patel R, Ray X, Shaw M, Shepherd J, Smyth G, Standen TS, Subramanian B, Greer PB, Clark CH. SEAFARER - A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice. *Radiother Oncol* 2022;171:121-128.
37. Lelliott EJ, Sheppard KE, McArthur GA. Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything? *NPJ Precis Oncol* 2022;6:26.
38. Li Z, Le Roux PY, Callahan J, Hardcastle N, Hofman MS, Siva S, Yamamoto T. Quantitative assessment of ventilation-perfusion relationships with gallium-68 positron emission tomography/computed tomography imaging in lung cancer patients. *Phys Imaging Radiat Oncol* 2022;22:8-12.
39. Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam C, Salles G. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv* 2022;6:2536-47.
40. McCann B, Higgins M, Kok DL, Hong W, Alipour R, Chua MST. Long-term control of melanoma adrenal metastasis treated with radiotherapy. *Melanoma Res* 2022;32:166-72.
41. McLean LS, Rischin D. In-transit cutaneous squamous cell carcinoma. *Med J Aust* 2022;216:401.
42. Muttiah C, Whittle JR, Oakman C, Lindeman GJ. PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. *Future Oncol* 2022;18:1805-16.
43. Nederlof I, Hajizadeh S, Sobhani F, Raza SEA, AbdulJabbar K, Harkes R, van de Vijver MJ, Salgado R, Desmedt C, Kok M, Yuan Y, Horlings HM. Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer. *NPJ Breast Cancer* 2022;8:56.
44. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as

first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. *Nat Med* 2022;28:735-42.

45. Obinata D, Funakoshi D, Takayama K, Hara M, Niranjana B, Teng L, Lawrence MG, Taylor RA, Risbridger GP, Suzuki Y, Takahashi S, Inoue S. OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer. *Sci Rep* 2022;12:6094.
46. Passaro A, Leigh N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba, II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. *Ann Oncol* 2022;33:466-87.
47. Peters S, James PA, Fatkin D, Zentner D. Pregnancy Outcomes in Females with Dilated Cardiomyopathy-Associated Rare Genetic Variants. *Circ Genom Precis Med* 2022;15:e003540.
48. Ritter AT, Shtengel G, Xu CS, Weigel A, Hoffman DP, Freeman M, Iyer N, Alivodej N, Ackerman D, Voskoboinik I, Trapani J, Hess HF, Mellman I. ESCRT-mediated membrane repair protects tumor-derived cells against T cell attack. *Science* 2022;376:377-82.
49. Robert C, Lewis KD, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Caro I, Forbes H, Shah K, Yan Y, Li H, McArthur GA, Ascierto PA. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF<sup>V600</sup> mutation-positive melanoma. *Ann Oncol* 2022;33:544-55.
50. Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips KA, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. *J Natl Cancer Inst* 2022;114:540-52.
51. Sherry NL, Gorrie CL, Kwong JC, Higgs C, Stuart RL, Marshall C, Ballard SA, Sait M, Korman TM, Slavin MA, Lee RS, Graham M, Leroi M, Worth LJ, Chan HT, Seemann T, Grayson ML, Howden BP. Multi-site implementation of whole genome sequencing for hospital infection control: A prospective genomic epidemiological analysis. *Lancet Reg Health West Pac* 2022;23:100446.
52. Simons M, Rapport F, Zurynski Y, Stoodley M, Cullis J, Davidson AS. Links between evidence-based medicine and shared decision-making in courses for doctors in training: a scoping review. *BMJ Open* 2022;12:e057335.
53. Smith Z, Barnett SA, Gorelik A, Pascoe DM, Manser RL. Strategies for the Management of Solitary Pulmonary Nodules: A Survey of Patient Preferences. *Ann Thorac Surg* 2022;113:1670-5.
54. Steffens D, Young J, Riedel B, Morton R, Denehy L, Heriot A, Koh C, Li Q, Bauman A, Sandroussi C, Ismail H, Dieng M, Ansari N, Pillinger N, O'Shannassy S, McKeown S, Cunningham D, Sheehan K, Iori G, Bartyn J, Solomon M. PREhabilitatiOn with pReoperative exercise and educaTion for patients undergoing major abdominal cancer surgery: protocol for a multicentre randomised controlled TRIAL (PRIORITY TRIAL). *BMC Cancer* 2022;22:443.
55. Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. *Lancet Haematol* 2022;9:e374-84.
56. Tonorezos ES, Cohn RJ, Glaser AW, Lewin J, Poon E, Wakefield CE, Oeffinger KC. Long-term care for people treated for cancer during childhood and adolescence. *Lancet* 2022;399:1561-1572.

57. Wang J, Mohan H, Larach JT, Heriot A, Warriar S. Hybrid robotic and laparoscopic hand-assisted proctocolectomy with complete mesocolic excision, ileal pouch-anal anastomosis and loop ileostomy - A video vignette. *Colorectal Dis* 2022;24:548.
58. Warren M, Emery J, Krishnasamy M, O Donnell A, Gough K. Pre-diagnostic routes to colorectal cancer in Central New Zealand: factors that lead to emergency presentation and longer diagnostic intervals at primary and secondary level care. *J Prim Health Care* 2022;14:48-56.
59. White VM, Lisy K, Ward A, Ristevski E, Clode M, Webber K, Emery J, IJzerman MJ, Afshar N, Millar J, Gibbs P, Evans S, Jefford M. Disparities in quality of life, social distress and employment outcomes in Australian cancer survivors. *Support Care Cancer* 2022;30:5299-309.
60. Wohlmuth C, Djedovic V, Kjaer SK, Jensen A, Glasspool R, Roxburgh P, DeFazio A, Johnatty SE, Webb PM, Modugno F, Lambrechts D, Schildkraut JM, Berchuck A, Thomsen LCV, Bjorge L, Høgdall E, Høgdall CK, Goode EL, Winham SJ, Matsuo K, Karlan BY, Lester J, Goodman MT, Thompson PJ, Pejovic T, Riggan MJ, Lajkosz K, Tone A, May T. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis. *Cancers* 2022;14:1954.
61. Woodford R, Zhou D, Lord SJ, Marschner I, Cooper WA, Lewis CR, John T, Yang JC, Lee CK. PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. *Future Oncol* 2022;18:1793-9.
62. Xu R, Choong PFM. Metastatic giant cell tumour of bone: a narrative review of management options and approaches. *ANZ J Surg* 2022;92:691-6.